We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Regulatory Uncertainty Slows Approvals of Novel Devices

Regulatory Uncertainty Slows Approvals of Novel Devices

August 14, 2015

Pioneer entrants for medical devices face a steeper hurdle than their drug counterparts in gaining approval, according to research from a Harvard professor.

“[I]n contrast to the early entrant advantages observed in drug regulation, first entrants in medical device markets experience a strong disadvantage in the regulatory approval process,” says Ariel Stern, an assistant professor of business administration, in Innovation under Regulatory Uncertainty: Evidence from Medical Technology.

Stern notes that pharmaceuticals “are a relatively homogeneous category of products,” with decades of regulation. “By comparison, medical devices and other non-drug medical products are far more heterogeneous and have a much shorter history of FDA oversight.”

The problem isn’t technological novelty or a lack of scientific knowledge on the part of reviewers, according Stern, but a lack of regulatory guidelines — particularly when it comes to devices with new product codes.

Stern points to implantable cardioverter defibrillators, which were first approved in 1983. Starting in 1998, some ICDs obtained a new product code as a result of modifications to the device. These later ICDs still experienced a regulatory delay, even though the FDA had years of experience evaluating them. Indeed, Stern says it takes 34 percent longer for pioneer medical device entrants with new product codes to go through the approval process than successive applicants.

While the lack of explicit evaluation criteria for devices contributes to this uncertainty and lengthy delays, the issuance of guidance explaining approval criteria for specific device types often reduces approval times, Stern says. Following issuance of guidance on drug-eluting stents, intravascular stents, heart valves and catheter ablation devices, approval times dropped by approximately 6.6, 5.5, 2.8 and 4.9 months, respectively.

While large firms are facing delays, the burden is worse for smaller companies, which have fewer resources and face prohibitive capital costs trying to get novel products to market.

Many smaller companies avoid innovative work because it’s too risky. Stern found that small devicemakers make up just 6.9 percent to 17.2 percent of pioneer entrants, compared with 36.4 percent to 54.5 percent in the pharmaceutical industry.

Suggestions for Improvement

Based on her research, Stern recommends the faster release of product-specific guidance documents. Earlier meetings between the FDA and sponsors could also lead to evaluation standards or guidelines before a submission is formally made.

She sees the 21st Century Cures Act as a potential avenue for restructuring the device approval process. Under the proposed legislation, devicemakers developing advanced technologies that either have no alternative or offer a significant improvement over existing alternatives could apply for a priority review designation before submitting an application (IDDM, May 1).

The legislation was approved by the U.S. House of Representatives last month in a 344-77 vote. The Senate is working to develop similar legislation (IDDM, July 10).

Stern tells IDDM that her research focuses broadly on the field of health economics and the economics of innovation. “The medical device industry is a place where the two fields meet, but very little academic health economics research is done,” she says. “My hope is to change that a bit with a few papers on the medical device innovation/regulatory process, and this is the first one in that effort.”

To read the report, visit www.fdanews.com/08-17-15-innovation.pdf. — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 12May

    Extractables and Leachables: 101

  • 19May

    CDRH’s New Accreditation Scheme for Conformity Assessment: Impacts on Your Future Testing Plans and FDA Submissions

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

  • 27May

    Evolving Clinical Trials: Continuing the Journey from Paper to Digital

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Fujifilm_Logo.gif

    Fujifilm Begins Late-Stage Trial of Avigan for COVID-19

  • CE mark

    DiaSorin’s 10-Minute COVID-19 Antibody Test CE Marked

  • WHO

    WHO Will Review Two COVID-19 Vaccines from China

  • CE mark

    Qiagen’s High Throughput COVID-19 Test Earns CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing